BrightSpring Health Services announced a secondary offering of 20 million shares at $41.15 per share, closing March 4, 2026.
Quiver AI Summary
BrightSpring Health Services, Inc. has priced a secondary offering of 20 million shares of its common stock at $41.15 per share, with the proceeds going entirely to the selling stockholders, which include an affiliate of Kohlberg Kravis Roberts & Co. and certain management members. BrightSpring will not sell any shares in this offering, which is expected to close on March 4, 2026, pending standard closing conditions. Additionally, BrightSpring has authorized the purchase of approximately 1.46 million shares from the underwriter at the same price, with that transaction closing simultaneously with the offering. Goldman Sachs & Co. LLC is the sole book-running manager for the offering. A prospectus related to the securities has been filed with the SEC and is available through Goldman Sachs. The press release highlights forward-looking statements regarding the company's expectations, which are subject to various risks and uncertainties.
Potential Positives
- BrightSpring Health Services is executing a secondary offering of 20,000,000 shares at a public offering price of $41.15 per share, indicating strong demand for its equity and potentially enhancing its market visibility.
- The company is proactively participating in the offering by authorizing a share repurchase of 1,464,807 shares, which reflects confidence in its own stock and may help support its share price.
- No shares are being sold by BrightSpring itself in the offering, which means the company is not diluting its ownership or raising funds directly, maintaining its balance sheet health.
- The offering is being managed by Goldman Sachs & Co. LLC, a highly reputable investment firm, enhancing the credibility of the offering in the eyes of investors.
Potential Negatives
- The offering of 20,000,000 shares by stockholders, including members of management, may signal a lack of confidence in the company's stock from insiders, potentially leading to negative perceptions among investors.
- The fact that no shares are being sold by BrightSpring itself could imply that the company is trying to avoid dilution of ownership or financial difficulties, which may raise concerns about its financial health.
- The reliance on forward-looking statements without guarantees of future performance highlights uncertainty, which could deter potential investors or raise concerns regarding company stability and future prospects.
FAQ
What is the latest announcement from BrightSpring Health Services?
BrightSpring Health Services announced a secondary offering of 20,000,000 shares of common stock at $41.15 per share.
Who are the Selling Stockholders in this offering?
The Selling Stockholders include an affiliate of Kohlberg Kravis Roberts & Co. L.P. and certain members of management.
Is BrightSpring selling shares in this offering?
No, BrightSpring is not selling any shares; all proceeds will be received by the Selling Stockholders.
When is the closing date for the offering?
The offering is expected to close on March 4, 2026, subject to customary closing conditions.
How can I obtain the prospectus for the offering?
You can request the preliminary prospectus from Goldman Sachs & Co. LLC at their Prospectus Department.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BTSG Insider Trading Activity
$BTSG insiders have traded $BTSG stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $BTSG stock by insiders over the last 6 months:
- GROUP PARTNERSHIP L.P. KKR sold 14,745,000 shares for an estimated $424,390,590
- PHOENIX AGGREGATOR L.P. KKR sold 14,745,000 shares for an estimated $424,390,590
- JON B ROUSSEAU (See Remarks) sold 235,000 shares for an estimated $6,763,770
- LISA A NALLEY (See Remarks) sold 20,000 shares for an estimated $575,640
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BTSG Revenue
$BTSG had revenues of $3.6B in Q4 2025. This is a decrease of -9.91% from the same period in the prior year.
You can track BTSG financials on Quiver Quantitative's BTSG stock page.
$BTSG Hedge Fund Activity
We have seen 192 institutional investors add shares of $BTSG stock to their portfolio, and 128 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KOHLBERG KRAVIS ROBERTS & CO. L.P. removed 15,154,305 shares (-19.7%) from their portfolio in Q4 2025, for an estimated $567,528,722
- BLACKROCK, INC. added 9,372,929 shares (+123.1%) to their portfolio in Q4 2025, for an estimated $351,016,191
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 3,958,691 shares (-78.7%) from their portfolio in Q4 2025, for an estimated $148,252,977
- VANGUARD GROUP INC added 2,928,953 shares (+30.5%) to their portfolio in Q4 2025, for an estimated $109,689,289
- FMR LLC removed 2,325,097 shares (-9.3%) from their portfolio in Q4 2025, for an estimated $87,074,882
- ROYAL BANK OF CANADA removed 2,198,147 shares (-99.6%) from their portfolio in Q4 2025, for an estimated $82,320,605
- STATE STREET CORP added 2,011,095 shares (+99.5%) to their portfolio in Q4 2025, for an estimated $75,315,507
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BTSG Analyst Ratings
Wall Street analysts have issued reports on $BTSG in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wells Fargo issued a "Overweight" rating on 01/07/2026
- BTIG issued a "Buy" rating on 12/23/2025
- Stephens & Co. issued a "Overweight" rating on 12/11/2025
- William Blair issued a "Outperform" rating on 12/08/2025
- BMO Capital issued a "Outperform" rating on 11/13/2025
- Mizuho issued a "Outperform" rating on 10/17/2025
- Morgan Stanley issued a "Overweight" rating on 10/14/2025
To track analyst ratings and price targets for $BTSG, check out Quiver Quantitative's $BTSG forecast page.
$BTSG Price Targets
Multiple analysts have issued price targets for $BTSG recently. We have seen 9 analysts offer price targets for $BTSG in the last 6 months, with a median target of $42.0.
Here are some recent targets:
- David Larsen from BTIG set a target price of $55.0 on 03/02/2026
- Stephen Baxter from Wells Fargo set a target price of $50.0 on 03/02/2026
- Ann Hynes from Mizuho set a target price of $42.0 on 12/18/2025
- Matthew Gillmor from Keybanc set a target price of $45.0 on 12/12/2025
- Dean Sublett from Stephens & Co. set a target price of $44.0 on 12/11/2025
- Joanna Gajuk from B of A Securities set a target price of $41.0 on 12/09/2025
- Sean Dodge from BMO Capital set a target price of $40.0 on 11/13/2025
Full Release
LOUISVILLE, Ky., March 02, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (NASDAQ: BTSG) (“BrightSpring” or the “Company”), a leading provider of home and community-based health services for complex populations, today announced the pricing of the previously announced underwritten secondary offering by certain of its stockholders (the “Selling Stockholders”), including an affiliate of Kohlberg Kravis Roberts & Co. L.P. and certain members of management, of an aggregate 20,000,000 shares of common stock of BrightSpring, at the public offering price of $41.15 per share. No shares are being sold by BrightSpring in the offering. The Selling Stockholders will receive all of the proceeds from this offering. The offering is expected to close on March 4, 2026, subject to customary closing conditions.
In addition, the Company has authorized, subject to the completion of the offering, the concurrent purchase from the underwriter, out of the 20,000,000 shares of common stock being sold as part of the secondary public offering, 1,464,807 shares of common stock at a price per share equal to the price per share to be paid by the underwriter to the Selling Stockholders. The underwriter will not receive any underwriting fees for the shares being repurchased by the Company. The closing of the share repurchase is conditioned on, and expected to occur simultaneously with, the closing of the offering. The offering is not conditioned upon the completion of the share repurchase.
Goldman Sachs & Co. LLC is acting as the sole book-running manager for the offering.
A shelf registration statement (including a prospectus) on Form S-3 relating to these securities was filed with the Securities and Exchange Commission on June 10, 2025 and became automatically effective upon filing. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering of these securities will be made only by means of a preliminary prospectus supplement and accompanying prospectus. Copies of the preliminary prospectus supplement and accompanying prospectus for the offering may be obtained from Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing [email protected].
Forward Looking Statements
The statements contained in this press release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on BrightSpring’s current expectations and are not guarantees of future performance. The forward-looking statements are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. These expectations, beliefs, and projections are expressed in good faith and BrightSpring believes there is a reasonable basis for them. However, there can be no assurance that these expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond BrightSpring’s control. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in BrightSpring’s filings with the SEC under caption “Risk Factors,” including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and subsequent other filings BrightSpring makes with the SEC from time to time. Any forward-looking statement in this press release speaks only as of the date of this release. BrightSpring undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws .
Contacts
Investor Relations:
David Deuchler, CFA
Gilmartin Group LLC
[email protected]
or
Media Contact:
Leigh White
[email protected]
502.630.7412